First Albany Downgrades Anika Therapeutics

Analyst William Plovanic says the bone proudcts manufacturer has seen slower-than-expected traction of its U.S. Orthovisc sales and a delay in its clinical program for CTA

First Albany downgrades bone proudcts manufacturer Anika Therapeutics (ANIK ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.